Radioactive nanoparticles target Tough-to-Treat cancers in new trial
NCT ID NCT06184035
Summary
This is a first-in-human study testing a new experimental drug called 177Lu-SN201 in adults with advanced solid tumors that have progressed despite standard treatments. The drug is a radioactive nanoparticle designed to accumulate in tumors. The main goals are to find a safe and effective dose and to see how the drug moves through and affects the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Research South Adelaide
RECRUITINGAdelaide, South Australia, 5000, Australia
Contact
-
St Vincent Hospital Melbourne
RECRUITINGMelbourne, Victoria, 3065, Australia
Contact
Conditions
Explore the condition pages connected to this study.